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Abstract
Objective: There is an established literature on cannabis expectancies and how these relate to patterns of
cannabis use and clinical outcomes. However increasingly we are becoming interested in how cannabis
expectancies shape the subjective experiences people have during drug use, and vice versa. Here we
present data reporting how cannabis expectancies relate to subjective experiences after cannabis.
Additionally we will determine whether an index of psychosis proneness (schizotypy) is related to
cannabis expectancies. Method: A sample of recreational cannabis users (n=137) completed the brief
Schizotypal Personality Questionnaire, the Cannabis Experiences Questionnaire and the Marijuana Effects
Expectancy Questionnaire. Results: Cannabis expectancies correlated with the subjective experiences
reported in the immediate high from cannabis. However, only Cognitive and Behavioural Impairment
expectancies were correlated with after effects from cannabis. There were no significant correlations
between schizotypy and cannabis expectancies. Conclusion: Cannabis expectancies are related to the
immediate experiences subjectively felt after smoking cannabis. Further research is necessary to
determine which clinically significant personality traits shape cannabis expectancies.
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Abstract
Objective: There is an established literature on cannabis expectancies and how these relate to patterns of cannabis
use and clinical outcomes. However increasingly we are becoming interested in how cannabis expectancies shape the
subjective experiences people have during drug use, and vice versa. Here we present data reporting how cannabis
expectancies relate to subjective experiences after cannabis. Additionally we will determine whether an index of
psychosis proneness (schizotypy) is related to cannabis expectancies.
Method: A sample of recreational cannabis users (n=137) completed the brief Schizotypal Personality Questionnaire,
the Cannabis Experiences Questionnaire and the Marijuana Effects Expectancy Questionnaire.
Results: Cannabis expectancies correlated with the subjective experiences reported in the immediate high from
cannabis. However, only Cognitive and Behavioural Impairment expectancies were correlated with after effects from
cannabis. There were no significant correlations between schizotypy and cannabis expectancies.
Conclusion: Cannabis expectancies are related to the immediate experiences subjectively felt after smoking
cannabis. Further research is necessary to determine which clinically significant personality traits shape cannabis
expectancies.

Keywords: Cannabis expectancies; Schizotypy; Substance use;
Schizophrenia and cannabis experiences
Introduction
Do expected effects of cannabis relate to the experiences people
have when using the drug? An individual’s expectancies for a substance
capture how they expect to be affected during substance use and are
shaped by information from the environment (e.g., media, peers,
observing others) as well as subjective experiences with that particular
substance when use occurs [1,2]. Traditionally, expectancies have
been considered in alcohol research, and are related to both adult and
adolescent drinking behaviours [3-5]. More recently expectancies have
been investigated in relation to cannabis use, with the previous results
from alcohol research largely being replicated [6-8]. Given the role
for expectancies to shape patterns of substance use, the investigation
of cannabis expectancies has relevance not only for substance use
problems in the general (psychologically healthy) population, but also
for individuals with serious mental health problems. For instance,
compared to the general population, rates of cannabis use are
elevated in patients with schizophrenia [9,10] and psychosis prone
healthy volunteers from the general population [11]. In those with
schizophrenia, substance use can lead to variability in treatment and
symptom outcomes [12]. Therefore determining whether cannabis
expectancies vary according to vulnerability for a mental illness such
as schizophrenia could highlight reasons for use, potentially explain
variations in subjective experiences with a substance and assist in
the development of effective psychological interventions to target
substance use in psychologically vulnerable populations [13].
Few studies have investigated cannabis expectancies in patients
with schizophrenia. Green, Kavanagh and Young [14] reported that
patients with psychosis had the same expectancies for cannabis and
used the same quantities on each occasion but with less frequency
when compared to healthy controls. However, psychosis patients
displayed more cannabis dependent-like behaviours (e.g., withdrawal
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symptoms) and were more driven to change their consumption than
healthy controls. Self-reported negative effects of cannabis predicted
of cannabis use over a four week follow up period in the patients
with psychosis but not control participants. Despite there being
no differences between the patients and controls on their overall
expectancies for cannabis, cannabis expectancies appeared to behave
in differential manner in the two groups.
Given that experiences with a substance shape expectations of
how the drug will affect people on future occasions, it is important to
consider subjective drug experiences in a systematic manner. Indeed,
the subjective experiences people have when smoking cannabis have
been related to both patterns of and reasons for cannabis use [14-16].
Aside from the management of psychotic symptoms, patients with
schizophrenia and healthy controls report using cannabis for the same
reasons [17]. Subjective experiences after using cannabis may change
as a psychotic disorder emerges in a young person. Those at risk for
developing psychosis report feeling more anxious, depressed and
suspicious after cannabis use [18]. Whilst, in those with recent onset
psychosis, the first psychotic symptoms occurred after cannabis use
[18]. Previously it has been reported that psychotic-like experiences
after cannabis use are related to psychosis proneness or schizotypy in
the general population [19-22].
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Given that the subjective experiences people report after cannabis
appear to differ according to schizotypy or psychosis proneness, it is also
possible that cannabis expectancies will also vary. Particularly since the
experiences people have with cannabis influence cannabis expectancies
[23]. Therefore we investigated the relationship between cannabis
expectancies, self-reported subjective experiences with cannabis and
schizotypy. Our primary hypothesize is that psychotic-like experiences
during the cannabis high will be related to, and predictive of, negative
expectancies and the pleasurable cannabis experiences to positive
cannabis expectancies. The relationship between cannabis expectancies
and other cannabis experiences will also be reported for completeness.
Given that the findings for expectancies differing between patients with
psychosis and healthy participants are limited we will test a secondary
hypothesize that negative cannabis expectancies will be positively
correlated with schizotypy scores. To ensure that our sample is in
keeping with previous studies we hypothesize that we will replicate
previous literature: expectancies will be related to patterns of cannabis
use, more specifically people who had used cannabis at least once
would score higher on the positive cannabis expectancies.

Method
Participants
An opportunity sample of 137 young adults (24% male; mean age
22.01 (SD 5.50) years) were recruited through a local university in
Manchester, UK. Participants did not receive financial compensation
for completing the study. Other data from these participants has been
reported in Barkus et al. [20].

Measures
Schizotypy: Participants completed the brief 22-itemed Schizotypal
Personality Questionnaire (SPQB) [24] comprising the most reliable
items from the longer Schizotypal Personality Questionnaire [25].
The SPQB produces a total score and three sub-scales: ‘Disorganized’
(SPQB-D), ‘Cognitive-Perceptual’ (SPQB-CP), ‘Interpersonal’
(SPQB-I) and a Total score.
Drug use: Frequency of cannabis use was categorized: Only once
or twice, At least once a year, At least once a week, and At least once
a month. We recorded when they smoked cannabis (During the
morning, during the day, during the evening, frequently during the day
and night) and other recreational drugs. Time of day when cannabis
was smoked was recorded as an indicator of the degree of intrusiveness
of cannabis use.
Experiences with cannabis: The properties of the Cannabis
Experience Questionnaire (CEQ) have been reported elsewhere [2022]. Briefly, participants respond to a list of experiences describing
immediate (‘high) and after effects associated with cannabis on a
Likert scale: Never, Occasionally, Sometimes, More often than not,
and Always. The items formed four subscales, two for the immediate
effects (Paranoid-Dysphoric and Euphoric) and two for after effects
(Amotivational and Psychosis after effects) [22]. The CEQ can be
completed by participants who smoke cannabis at least once in their
life.
Marijuana effects expectancy questionnaire: The MEEQ [26]
was designed to record expectations for the effects of cannabis; it
can be completed regardless of whether an individual has taken
cannabis. It has six subscales: Cognitive and Behavioural Impairment
(CBI), Relaxation and Tension Reduction (RTR), Social and Sexual
Facilitation (SSF), Perceptual Cognitive Enhancement (PCE), Global
Negative Effects (GNE), and Craving and Physical Effects (CPE).
J Addict Res Ther
ISSN:2155-6105 JART an open access journal

Procedure
Respondents completed the CEQ, MEEQ and the SPQB as fully and
honestly as possible in their own time and returned them to a labelled
post box in a communal area of the university. Respondents were only
identifiable by a number. The current data analysis was performed
using SPSS version 15. The study had ethical approval as part of a larger
project examining psychosis risk factors in a non-clinical population.

Statistical analysis
All variables approximated to a normal distribution except the SPQB
subscales which required a logarithmic transformation. In the interests
of reducing false positive results the significance level to be reached
was 1%. In general terms, t-tests were used when the independent
variable had two groups, analysis of variance (ANOVA) was used
when the independent variable had three or more groups. Scheffe
post hoc analysis was used if the ANOVAs proved to be significant.
Chi-square tests were used when associations between categorical
variables were being tested. The Pearson’s correlations were used to
explore the relationship between the MEEQ subscales schizotypy and
cannabis experiences. Untransformed means are presented for ease of
interpretation. In addition, regression analyses have been performed to
determine which variables predict cannabis experiences.

Results
Participants
72.5% of our sample reported having used cannabis at least once.
There was no association between gender and smoking cannabis or
polydrug status. Of the total sample, 40.9% had used only cannabis,
while 33.6% of the total sample were polydrug users (i.e., had used at
least one other drug besides cannabis). The number of other drugs
(besides cannabis) used by participants varied between 1 (41% of the
polydrug users) and 10 (0.7%). Other recreational drugs of choice
(listed according to frequency of reporting) included cocaine (19%),
ecstasy (19%), LSD (13%), amphetamine (11%), magic mushrooms
(7%), poppers (7%) and ketamine (4%). Drugs used by fewer than 2%
of participants included: solvents, GHB, nutmeg, benzodiazepines,
MDA, opiates and barbiturates. Three participants who had not
smoked cannabis but had used other drugs (LSD, cocaine or morphine)
were included in the analyses reported below as non-cannabis users.
There were no gender differences on MEEQ subscales, nor any
associations between gender and patterns of cannabis or other drug
use. There were no significant differences on the MEEQ subscales for
the frequency of cannabis use. In keeping with the previous literature
males had higher scores on the disorganised dimension from the SPQB
(Male: 2.64 (SD=1.85), Female=1.56 (SD=1.65); t=3.41, df=46.62,
p=0.002). There were no differences for cannabis use status, polydrug
use status or frequency of use on the schizotypy scores.

MEEQ and SPQB
There were no significant correlations between the subscales
from the MEEQ and the SPQB subscales. Given that there were no
significant correlations between MEEQ and SPQB, regression models
using MEEQ subscales to predict schizotypy were not persuade further.

MEEQ and cannabis use
There were significant differences between cannabis users and
non-users on two of the MEEQ subscales. For the SSF subscale (t=3.99,
df=58.33, p<0.001) those who had not smoked cannabis scored
significantly higher (mean=5.41, SD=2.26) than those who had smoked
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cannabis (mean=3.80, SD=1.80). For the GNE subscale (t=5.55, df=135,
p<0.001) those who had not smoked cannabis had higher negative
evaluations (mean=4.72, SD=2.24)) compared to those who had used
cannabis (mean=2.39, SD=2.21) (Table 1).

F(6,92) =6.08, p<0.001), high Cognitive and Behavioural Impairment,
low Relaxation and Tension Reduction, and high Perceptual Cognitive
Enhancement scores predicted these immediate experiences from
cannabis (Table 3).

Participants were divided into three groups according to whether
they had used no drug (n=35), cannabis only (n=56) or had used
one other drug besides cannabis (polydrug use; n=46). There were
significant differences on four MEEQ subscales (Table 1). Both the no
drug group and the polydrug group (at a trend level) scored higher than
the cannabis only group on the CBI subscale. The no drug group scored
significantly higher on the SSF compared to the cannabis only and the
polydrug groups. For the GNE subscale the no drug group scored
significantly higher than both the cannabis only and the polydrug
groups. For the RTR subscale the no drug group had significantly
higher scores than the polydrug group.

The results for the immediate Euphoric experiences (R2=0.380,
adjusted R2=0.339; F(6,92) =9.39, p<0.001) are displayed in Table 4.
Low Cognitive and Behavioural Impairment, high Perceptual Cognitive
Enhancement and high Craving and Physical Effects were predictive
of high endorsement of Euphoric Experiences in the immediate high
from cannabis.

MEEQ and CEQ subscales
The correlations between the MEEQ subscales and the CEQ
subscales are presented in Table 2. Both the SSF and the GNE
subscales did not correlate significantly with any CEQ subscales. There
were significant correlations between the MEEQ and the immediate
response to cannabis subscales, only the CBI subscale from the MEEQ
was correlated with the after effect subscales from the CEQ.
In order to determine which MEEQ subscales provided unique
variance in predicting cannabis experiences, a series of regression
models using Enter method were performed. The results of these
will now be described. When considering the immediate PsychosisDysphoric experiences from cannabis (R2=0.284, adjusted R2=0.237;

Table 5 displays the results for the regression model predicting
Amotivational after effects from cannabis (R2=0.290, adjusted
R2=0.244; F(6,92) =6.26, p<0.001). High scores on Cognitive and
Behavioural Impairment, Perceptual Cognitive Enhancement, and low
scores on Relaxation and Tension Reduction predicted high scores on
for Amotivational after effects.
Finally, the MEEQ subscales which predicted Psychosis-like after
effects were also considered (R2=0.213, adjusted R2=0.161; F(6,92)
=4.14, p=0.001). High scores on Cognitive and Behavioural Impairment
and low scores on Relaxation and Tension Reduction were significant
of the Psychosis-like after effects (Table 6).

Discussion
The study examined the relationship between cannabis expectancies,
subjective cannabis experiences and schizotypy. Those who had
not used cannabis had higher scores on the Global Negative Effects
subscale and Social and Sexual Facilitation subscales from the MEEQ.

Drug use

F value, df=2,134, p value

Scheffe values (p value)

6.57 (2.32)

F=5.06, p=0.008

No drugs V cannabis only (0.017)
Cannabis only V Polydrugs (trend 0.058)

4.16 (1.96)

3.46 (1.66)

F=10.74, p<0.001

No drugs V cannabis only (0.009)
No drugs V Polydrugs (<0.001)

4.66 (2.26)

2.75 (2.32)

2.20 (2.20)

F=12.57, p<0.001

No drugs V cannabis only (0.001)
No drugs V Polydrugs (<0.001)

6.00
(2.13)

5.46
(1.94)

4.61
(2.12)

F=4.12, p=0.01

No drugs V Polydrugs (0.012)

No drugs (n=35)

Cannabis Only (n=56)

Polydrug use (n=46)

CBI

6.89 (1.75)

5.48 (2.47)

SSF

5.46 (2.21)

GNE
RTR

Key: CBI: Cognitive and Behavioural Impairment; RTR: Relaxation and Tension Reduction; SSF: Social and Sexual Facilitation; PCE: Perceptual Cognitive Enhancement;
GNE: Global Negative Effects; CPE: Craving and Physical Effects (CPE).
Table 1: The effects of polydrug use status on MEEQ subscales.
Paranoid Dysphoric

Euphoric

Amotivational After Effects

Psychosis-like After Effects

CBI

0.434 (p<0.001)

ns

0.463 (p<0.001)

0.395 (p<0.001)

RTR

ns

0.349 (p<0.001)

Ns

ns

PCE

0.232 (0.021)

0.473 (p<0.001)

Ns

ns

CPE

0.200 (0.047)

0.233 (0.020)

Ns

ns

Key: n=99 (cannabis users only). CBI: Cognitive and Behavioural Impairment; RTR: Relaxation and Tension Reduction; SSF: Social and Sexual Facilitation; PCE:
Perceptual Cognitive Enhancement; GNE: Global Negative Effects; CPE: Craving and Physical Effects (CPE).
Table 2: The correlations between the MEEQ and the CEQ subscales.
Unstandardized Coefficients

Standardized Coefficients

MEEQ Subscale

B

Std. Error

Beta

t

Sig.

Cognitive and Behavioural Impairment

1.882

.538

.360

3.500

0.001

Relaxation and Tension Reduction

-1.924

0.739

-0.309

-2.604

0.011

Social and Sexual Facilitation

-.217

0.822

-0.030

-0.264

0.793

Perceptual Cognitive Enhancement

1.924

0.710

0.296

2.709

0.008

Global Negative Effects

-0.357

0.646

-0.061

-0.553

0.582

Craving and Physical Effects

0.774

0.778

0.096

0.995

0.322

Table 3: The Enter Regression model results for Psychosis-Dysphoric immediate cannabis experiences.

J Addict Res Ther
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Unstandardized Coefficients

Standardized Coefficients

MEEQ Subscale

B

Std. Error

Beta

t

Sig.

Cognitive and Behavioural Impairment

-0.912

0.337

-0.259

-2.705

0.008

Relaxation and Tension Reduction

0.177

0.463

0.042

0.383

0.703

Social and Sexual Facilitation

0.153

0.516

0.032

0.297

0.767

Perceptual Cognitive Enhancement

2.386

0.445

0.545

5.358

0.000

Global Negative Effects

-0.731

0.405

-0.184

-1.804

0.074

Craving and Physical Effects

1.429

0.488

0.264

2.928

0.004

Table 4: The Enter Regression model results for Euphoric immediate cannabis experiences.
Unstandardized Coefficients

Standardized Coefficients

MEEQ Subscale

B

Std. Error

Beta

t

Sig.

Cognitive and Behavioural Impairment

1.235

0.279

0.454

4.430

0.000

Relaxation and Tension Reduction

-0.908

0.383

-0.280

-2.369

0.020

Social and Sexual Facilitation

-0.202

0.427

-0.054

-0.473

0.637

Perceptual Cognitive Enhancement

0.797

0.368

0.235

2.163

0.033

Global Negative Effects

-0.419

0.335

-0.137

-1.251

0.214

Craving and Physical Effects

0.180

0.404

0.043

0.445

0.657

Table 5: The Enter Regression model results for Amotivational after Effects from cannabis.
Unstandardized Coefficients

Standardized Coefficients

MEEQ Subscale

B

Std. Error

Beta

t

Sig.

Cognitive and Behavioural Impairment

0.494

0.136

0.392

3.634

0.000

Relaxation and Tension Reduction

-0.369

0.187

-0.246

-1.972

0.052

Social and Sexual Facilitation

-0.037

0.208

-0.021

-0.176

0.861

Perceptual Cognitive Enhancement

0.308

0.180

0.196

1.711

0.090

Global Negative Effects

-0.082

0.163

-0.058

-0.503

0.616

-0.091

0.197

-0.047

-0.463

0.645

Craving and Physical Effects

Table 6: The Enter Regression model results for Psychosis-like After Effects from cannabis.

This suggests users minimise the general negative effects of cannabis,
while non-users perceive cannabis to be more socially facilitating than
users. Consequently, user’s expectations about cannabis are not simply
more positive than non-users as hypothesized, rather it appears costbenefit reasoning exists potentially with anticipated positive effects
not living up to expectations but negative expectancies about cannabis
also not being realised after use. This is supported by previous research
reporting that those who had not smoked cannabis have higher global
negative expectations [6-8,14]. Many of the reason given by patients
for cannabis use are centred on social situations [17], although in the
current sample non-users had higher expectations for cannabis to be
relaxing, socially and sexually facilitating. This suggests the perceived
reasons for use in patients may not directly align with drug expectancies
in users, particularly given that there were no significant correlations
between schizotypy scores and cannabis expectancies.
When considering the degree of exposure to recreational drugs,
the Global Negative Effects subscale and Social and Sexual Facilitation
subscales were also sensitive to group differences. There was a linear
effect for Social and Sexual Facilitation, Global Negative Effects and
Relaxation and Tension Reduction subscales from the MEEQ with the
no drug exposure group scoring highest, cannabis only an intermediary
group and the polydrug group scoring the lowest. Polydrug users and
those with no exposure to recreational drugs had higher ratings for
the Cognitive Behavioural Impairment from cannabis. These results
suggest polydrug users are more likely to minimise general negative
effects of cannabis, but also do not perceive the relaxing benefits
stereotypically associated with cannabis. However, we did not explicitly
ask participants whether they used cannabis in combination with other
recreational drugs so cannot conclude whether these scores reflect a
general attitude to drugs or the effects of using other drugs contiguous
with cannabis.
J Addict Res Ther
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There was partial support for the hypothesis that psychotic-like
experiences after cannabis use will be related to negative expectancies,
and pleasurable cannabis experiences will be related to positive
cannabis expectancies. Only the Cognitive and Behavioural Impairment
subscale from the MEEQ was associated with both the immediate
and after effects from cannabis, perhaps reflecting a recognition that
the cognitive effects of cannabis persist after the initial high from
cannabis has abated. The two immediate cannabis effects subscales
from the CEQ were correlated with nearly all of the MEEQ subscales.
In the regression models the Cognitive and behavioural Impairment
subscale were predictive of all the cannabis experiences; Perceptual
Cognitive Enhancement scores were predictive of the immediate
cannabis experiences and the Amotivational after-effects. Lower scores
on Relaxation and Tension Reduction were predictive of the more
negative experiences from cannabis in both the immediate high and
the after effects; this would suggest that those who have expectancies
of enjoying cannabis are less likely to experience deleterious subjective
effects. Conversely high Craving and Physical Effects expectancies
were predictive of Euphoric immediate effects; perhaps pointing
to immediate enjoyment of the high being a motivation for future
use. The reasons for cannabis use are primarily focused upon the
immediate effects of cannabis [17]. Peters et al. [18] reported that
their patient groups (clinical high risk for and recent onset patients
with psychosis) reported longer lasting subjective after effects from
cannabis than healthy controls. Perhaps individuals, who are sensitive
to the immediate high from cannabis, experience more after effects
as well. Sensitivity to the effects of the immediate high from cannabis
could strongly reinforce cannabis expectancies and shape expectations
for future effects when smoking cannabis. An alternative explanation
for cannabis expectancies being correlated with the immediate rather
than after effects from cannabis, may be found in focus that the media
Volume 6 • Issue 4 • 1000249
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places on the immediate high from cannabis, paying little attention to
the potential for longer lasting after effects. Learning environment and
exposure to media messages will shape cannabis expectancies, which
in turn may shape experiences, which will reciprocate to potentially
modify expectancies over time with repeated exposure to the drug.
Schizotypy scores were not related to expectancies. This suggests
that those who score high or low on schizotypy have the same
expectations about the effects of cannabis. Perhaps lending support
for individual differences in cannabis experiences being underpinned
by biological (genes, dopamine regulation) rather than social factors
(openness to unusual experiences). Additionally it may offer tentative
evidence against those with higher schizotypy scores using cannabis
to self-medicate. In support of these findings, previously Hides et al.
[27] reported that cannabis expectancies were not related to psychotic
symptoms in patients. However, some studies report patients with
psychosis use cannabis to enhance mood [17,28]. This could be an
indirect effect on symptoms and assist in facilitating social interactions.
It would be possible to examine this mediating effect in healthy
individuals with high schizotypy scores.
The current study only used a brief schizotypy measure and it
may be that the items which are sensitive to cannabis expectancies
were not included. There may be other aspects of personality which
are more closely related to cannabis expectancies and use such as
impulsivity (see data on the acquired preparedness model) [29] than
schizotypy. Alternatively the effect of schizotypy may be too small to
detect in the relatively small sample size reported here. Furthermore
we used a relatively high functioning sample that only used cannabis
recreationally. Collecting data from a different sample could produce
alternative results. In the general population it may be possible to
recruit individuals who use cannabis heavily, perhaps resulting in
associations between schizotypy and expectancies.
In conclusion we found similar findings to previous research for the
effects of patterns of use on cannabis expectancies. Schizotypy scores
and cannabis expectancies were not related. Immediate effects from
cannabis were correlated with a greater number of cannabis expectancy
subscales than the cannabis after effects. Replication of the current data
is required in a larger sample and with a more detailed schizotypy scale.
Furthermore other personality traits need to be investigated which may
be related to both cannabis experiences and expectancies. Additionally
with a larger sample other analysis techniques such as mediation
and structural equation modelling would be beneficial to address
the direction of the relationship between cannabis expectancies,
experiences and possible role schizotypy may play.
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